Nektar Therapeutics (NKTR) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-13

Business type: Asset play

How it makes money

It currently generates no commercial product revenue, relying entirely on developing clinical-stage drug candidates such as rezpegaldesleukin.

Nektar Therapeutics operates as a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy.

Because its drug candidates are still undergoing preclinical and clinical development, the company does not yet sell commercial products or generate product sales revenue. Its financial results depend entirely on the future clinical success and eventual commercialization of its pipeline, particularly its lead immunotherapy candidate rezpegaldesleukin.

What protects it: the moat

Management asserts that its deep understanding of immunology and proprietary drug candidates create competitive advantages, though none are yet secured by approved products.

The company relies on its internal research and development expertise to identify and advance novel immunomodulatory agents targeting autoimmune diseases and cancer.

However, because its pipeline remains in clinical development without approved commercial products, the durability of its competitive position depends entirely on future regulatory approvals and the successful execution of clinical trials.

What growth costs

It funds ongoing research and development expenses, including clinical trials for its pipeline candidates, to advance its programs.

The company makes significant investments in building and advancing its pipeline of drug candidates, particularly following the termination of its prior licensing agreement with Eli Lilly and Company.

With the return of full rights to rezpegaldesleukin, the company now bears all development costs, including funding clinical studies such as the Phase 2b trials in atopic dermatitis and alopecia areata.

What could damage it

Failure of its lead drug candidate rezpegaldesleukin in clinical development would severely impair its business prospects and financial condition.

The company's future success depends heavily on the clinical and regulatory success of rezpegaldesleukin across various autoimmune indications.

If clinical trials fail to meet their endpoints or if regulatory authorities do not approve the drug, the company would lose its primary pathway to commercialization, directly undermining its entire operational strategy.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Other companies in Biotechnology